CHELSEA WHITE: Open Payments
NPI 1205470317 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,261 in 48 payments from 22 companies in 2025. Trend: 2023 $444 · 2024 $801 · 2025 $2,261
Food & beverage: $1,481Consulting: $780
| Company | Payments | Amount |
|---|---|---|
| Genmab U.S., Inc. | 3 | $836 |
| PFIZER INC. | 7 | $259 |
| ABBVIE INC. | 8 | $150 |
| Janssen Biotech, Inc. | 2 | $136 |
| GENZYME CORPORATION | 1 | $126 |
| Incyte Corporation | 1 | $125 |
| AstraZeneca Pharmaceuticals LP | 4 | $105 |
| Regeneron Healthcare Solutions, Inc. | 4 | $91 |
| Novartis Pharmaceuticals Corporation | 2 | $57 |
| Janssen Scientific Affairs, LLC | 1 | $55 |
Products named: Epkinly, ELREXFIO, SARCLISA, Monjuvi, RYBREVANT, TECVAYLI, LYNOZYFIC, IMFINZI.
Industry payments across TX — which companies pay providers there.
